Market Is Estimated To Witness High Growth Owing To Its Promising Pipeline And Strong R&D Investments.
Antibody Drug Conjugates The Antibody Drug Conjugates Market is estimated to be valued at US$ 5.38 billion in 2023 and is expected to exhibit a CAGR of 14.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Antibody-drug conjugates (ADCs) are bioconjugate compounds used for targeted drug delivery. They consist of monoclonal antibodies attached to a small-molecule drug or cytotoxic agent. The monoclonal antibody helps target the cancer cells and the cytotoxic agent then kills those cells. ADCs help deliver highly potent anti-cancer drugs directly to the tumor while limiting side effects in non-cancerous cells. Market Dynamics: The growing antibody drug conjugates market is driven primarily by its promising pipeline and strong R&D investments from major players. Several late-stage pipelines are expected to be commercialized during the forecast period, propelling market growth. For instance, AstraZene...